NRF2系统在人类慢性肾脏病中的系统综述:改变、干预及与发病率的关系
该系统综述检索PubMed和EMBASE数据库,纳入32项研究,评估CKD患者中NRF2及其效应分子NQO1和HO-1的改变、对干预的反应及与临床参数的关系。多数分析显示CKD患者NRF2水平降低,NQO1和HO-1变化不一,且与炎症、合并症及肾脏损伤严重程度相关。部分干预可增加NRF2系统组分,但有效性和临床相关性需高质量临床研究进一步验证。
要点
- CKD患者中NRF2表达多数分析显示下调。
- NQO1和HO-1变化不一,与炎症、合并症及肾损伤严重程度相关。
- 部分干预可增加NRF2系统组分,但需高质量临床研究验证。
核心结论
- CKD患者中NRF2表达下调,NQO1和HO-1变化不一且与炎症、合并症及肾损伤严重程度相关。
- 增加NRF2系统组分的干预已有描述,但其有效性和临床相关性需进一步高质量临床研究。
研究设计与样本
- 系统检索PubMed和EMBASE数据库,初检1373篇文章,最终纳入32项符合标准的研究。
主要发现
- 多数CKD患者分析中NRF2水平降低。
- 半数分析显示NQO1水平与对照相似或升高,另半数分析显示降低。
- 多数研究报道CKD患者HO-1水平升高或与对照相似。
- CKD 1-4期患者中,NRF2系统组分与肾脏疾病严重程度标志物呈正相关。
- NQO1/HO-1水平与炎症和合并症呈正相关;三分之一的研究显示基因表达与蛋白水平变化不一致。
关键数值与推荐
- 三分之二的干预研究(其中50%为饮食干预,如使用抗性淀粉)报告NRF2、NQO1或HO-1增加。
临床怎么用
- NRF2系统组分可能作为CKD严重程度和炎症/合并症的关联指标,但尚不能指导临床干预决策。
局限性
- 干预研究的有效性和临床相关性需进一步高质量临床研究验证。
- 需结合基因表达与蛋白分析以全面理解CKD中NRF2系统的改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nuclear factor erythroid 2-related factor 2 (NRF2) and its effectors NAD(P)H:quinoneoxidoreductase 1 (NQO1) and haem oxygenase 1 (HO-1) are of interest in kidney disease. We therefore reviewed studies about their status in patients with chronic kidney disease (CKD). METHODS: We undertook systematic searches of PubMed and Excerpta Medica dataBASE (EMBASE) databases. Alterations of NRF2, NQO1 and HO-1 in CKD, their responses to interventions and their relation to clinically relevant parameters were reported. RESULTS: We identified 1373 articles, of which 32 studies met the inclusion criteria. NRF2 levels were decreased in the majority of analyses of CKD patients. Half of the analyses showed a similar or increased NQO1 level versus control, whereas in half of the analyses NQO1 was decreased. Most of the studies reported either an increased or similar HO-1 level in CKD patients compared with controls. For patients with CKD Stages 1-4, studies reported positive correlations to markers of kidney disease severity. Also, positive associations of NQO1/HO-1 levels to inflammation and comorbidities were reported. One-third of the studies showed discordant changes between gene expression and protein level of NRF2 system components. Two-thirds of intervention studies (50% dietary, such as using resistant starch) reported an increase of NRF2, NQO1 or HO-1. CONCLUSIONS: In patients with CKD, NRF2 expression was downregulated, while NQO1 and HO-1 showed varying alterations related to inflammation, comorbidities and severity of kidney damage. Interventions that increased NRF2 system components were described, but their effectiveness and clinical relevance require further clinical studies of high quality. Research on gene expression together with protein analyses is indispensable to understand NRF2 system alterations in CKD.
引用
- Juul-Nielsen C, Shen J, Stenvinkel P, et al. Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity. Nephrol Dial Transplant. 2022. PMID: 33547785. doi:10.1093/ndt/gfab031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。